Preparation and characterization of amphiphilic poly-N-vinylpyrrolidone nanoparticles containing indomethacin

Amphiphilic poly-N-vinylpyrrolidone derivatives (Amph-PVP) with different molecular weight of hydrophilic PVP fragment and one terminal hydrophobic n-alkyl fragment of different length were synthesized for preparation of nano-scaled particles in aqueous media. To estimate novel polymer efficiency and perspective as basis for drug delivery systems, the polymeric micelle-like particles were prepared by dialysis and solvent evaporation methods. Indomethacin was incorporated into hydrophobic inner core of these nanoparticles as a typical model drug. From the dynamic light-scattering measurements, the size of particles formed was less than 200 nm with narrow monodisperse size distribution and nanoparticles size slightly increased with the amount of indomethacin encapsulated into inner core of Amph-PVP particles. The critical aggregation concentration values for prepared polymer samples determined by fluorescence spectroscopy were in micromole range which is lower than it is for common low molecular weight surfactants. As the hydrophobic fragment of amphiphilic polymer increased, the critical aggregation concentration values decreased. An increase of polymer hydrophilic fragment molecular weight produced larger nanoaggregates. In vitro release experiments using indomethacin-loaded Amph-PVP nanoparticles exhibited the sustained release behavior without any burst effect for most polymer samples.     

Biodegradable nanoparticles for improved kidney bioavailability of rhein: preparation,characterization, plasma,and kidney pharmacokinetics

The aim of this work is to develop biodegradable nanoparticles for improved kidney bioavailability of rhein (RH). RH-loaded nanoparticles were prepared using an emulsification solvent evaporation method and fully characterized by several techniques. Kidney pharmacokinetics was assessed by implanting a microdialysis probe in rat's kidney cortex. Blood samples were simultaneously collected (via femoral artery) for assessing plasma pharmacokinetics. Optimized nanoparticles were small, with a mean particle size of 132.6?±?5.95?nm, and homogeneously dispersed. The charge on the particles was nearly zero, the encapsulation efficiency was 62.71?±?3.02%, and the drug loading was 1.56?±?0.15%. In vitro release of RH from the nanoparticles showed an initial burst release followed by a sustained release. Plasma and kidney pharmacokinetics showed that encapsulation of RH into nanoparticles significantly increased its kidney bioavailability (AUC_kidney/AUC_plasma?=?0.586?±?0.072), clearly indicating that nanoparticles are a promising strategy for kidney drug delivery.     

S-adenosyl-l-methionine (SAMe)-loaded nanochitosan particles: synthesis,characterisation and in vitro drug release studies

Chitosan-based drug carriers are being widely exploited for sustained and targeted delivery in cancer, anti-depression and nutritive therapeutics. In this paper, we report the preparation of S-adenosyl-l-methionine (SAMe) drug-loaded nanochitosan-based tablets and the sustained delivery of the drug substance in simulated intestinal conditions through an in vitro study. The convertibility of high molecular weight commercial chitosan to nanoparticles by ionic gelation using potassium pyrophosphate was achieved without employing harsh reaction conditions through an intermediate water-soluble chitosan preparation. The prepared nanochitosan particles with an average size of 85–127 nm showed good drug-loading capacity. In vitro release studies showed a continuous and slow release of the drug over 14 hours. Different kinetics models were applied to drug release data in order to evaluate the releasing mechanism. The drug release data fit well into the Higuchi expression, suggesting a diffusion-controlled drug delivery. The diffusional coefficient of 1.83 indicated that the drug release from the chitosan matrix was through swelling of the matrix. Agreement of the kinetic data with Higuchi and Korsmeyer–Peppas models have led us to conclude that the delivery of the SAMe drug from the nanochitosan drug carrier took place by the diffusion-controlled swelling mechanism described as Super case II transport. The prepared nanochitosan matrix was also found to be an environment-sensitive vehicle suitable for controlled drug delivery.     

Preparation,characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting

Objective: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder manifested by cognitive, memory deterioration and variety of neuropsychiatric symptoms. Donepezil is a reversible cholinesterase inhibitor used for the treatment of AD. The purpose of this work is to prepare a nanoparticulate drug delivery system of donepezil using poly(lactic-co-glycolic acid) (PLGA) for sustained release and efficient brain targeting.

Materials and methods: PLGA nanoparticles (NPs) were prepared by the solvent emulsification diffusion–evaporation technique and characterized for particle size, particle-size distribution, zeta potential, entrapment efficiency, drug loading and interaction studies and in vivo studies using gamma scintigraphy techniques.

Results and discussion: The size of drug-loaded NPs (drug polymer ratio 1:1) was found to be 89.67?±?6.43?nm. The TEM and SEM images of the formulation suggested that particle size was within 20–100?nm and spherical in shape, smooth morphology and coating of Tween-80 on the NPs was clearly observed. The release behavior of donepezil exhibited a biphasic pattern characterized by an initial burst release followed by a slower and continuous sustained release. The biodistribution studies of donepezil-loaded PLGA NPs and drug solution via intravenous route revealed higher percentage of radioactivity per gram in the brain for the nanoparticulate formulation as compared with the drug solution (p?Conclusion: The high concentrations of donepezil uptake in brain due to coated NPs may help in a significant improvement for treating AD. But further, more extensive clinical studies are needed to check and confirm the efficacy of the prepared drug delivery system.     

Synthesis and characterization of paclitaxel-imprinted nanoparticles for recognition and controlled release of an anticancer drug

Imprinted nanoparticles as drug delivery carriers have been considered because owing to their cross-linked network, they act as the drug reservoir for controlled release. In this study, selective MIPs nanoparticles of paclitaxel (PTX) were successfully developed for application in the biological molecular recognition and in the design of new anticancer drug delivery systems. The MIPs nanoparticles prepared by miniemulsion polymerization technique using methacrylic acid (MAA) and methyl methacrylate as non-covalent functional monomer, ethylene glycol dimethacrylate and trimethylolpropane trimethacrylate (TRIM) as cross-linker agent, azobisisobutyronitrile as initiator, and hexadecane as hydrophobic agent. In order to prepare of MIP nanoparticles, the synthesis conditions and effective parameters, such as: cross-linker agent, different molar ratios of template–functional monomer–cross-linker agent, were investigated. In addition, the effect of different molar ratios of template and monomers on polymers binding and morphology were characterized. Structure and thermal properties of MIPs were confirmed by FT-IR spectroscopy and thermogravimetric analysis. Imprinted nanoparticles showed significant drug loading and encapsulation efficiency, 17.8 and 100 %, respectively. The particle size of MIP nanoparticles varies between 187 and 726 nm, according the SEM images and laser light scattering data. The imprinted nanoparticles showed satisfactory affinity (84 %) to PTX with a binding of 12 times higher than non-imprinted nanoparticles in biological samples when MAA and TRIM were used as functional and cross-linker monomer, respectively. Results from release experiments of MIPs showed a very slow and controlled release of PTX which would be helpful for sustained drug delivery.     

Preparation of embolic NEMs loading capecitabine

The nanoparticles-embedded microcapsules (NEMs) with smooth surface, good sphericity, excellent dispersivity and uniform particle size distribution were prepared by emulsification combined with electrospraying to extend the sustained release performance of the embolic microcapsules loading capecitabine (CAP). The sodium alginate and chitosan with good biocompatibility were used as the materials and CAP as a small-molecule model drug. The drug loading, encapsulation efficiency and drug release of CAP in the NEMs were investigated. The results showed that the drug-loading and encapsulation efficiency both increased with the increment of chitosan and CAP concentration. The maximum values of drug loading and encapsulation efficiency were 1.97 and 18.01 % respectively when initial CAP concentration was 5.0 g/L and chitosan molecular weight 100 kDa. The cumulative release rate of CAP released from the NEMs was lower than 30 % in 0.5 h, which indicated that there was no obvious initial burst release behavior. In the subsequent 240 h, the release results confirmed that the NEMs had better sustained release properties compared to pure microcapsules, and it might be a new anticancer drug delivery system in the future studies.     

Lysozyme-loaded lipid-polymer hybrid nanoparticles: preparation,characterization and colloidal stability evaluation

Context: Lipid-polymer hybrid nanoparticles (LPNPs) are polymeric nanoparticles enveloped by lipid layers, which have emerged as a potent therapeutic nanocarrier alternative to liposomes and polymeric nanoparticles.

Objective: The aim of this work was to develop, characterize and evaluate LPNPs to deliver a model protein, lysozyme.

Materials and methods: Lysozyme-loaded LPNPs were prepared by using the modified w/o/w double-emulsion-solvent-evaporation method. Poly-?-caprolactone (PCL) was used as polymeric core material and tripalmitin:lechitin mixture was used to form a lipid shell around the LPNPs. LPNPs were evaluated for particle size distribution, zeta potential, morphology, encapsulation efficiency, in vitro drug release, stability and cytotoxicity.

Results: The DLS measurement results showed that the particle size of LPNPs ranged from 58.04?±?1.95?nm to 2009.00?±?0.52?nm. The AFM and TEM images of LPNPs demonstrate that LPNPs are spherical in shape. The protein-loading capacity of LPNPs ranged from 5.81% to 60.32%, depending on the formulation parameters. LPNPs displayed a biphasic drug release pattern with a burst release within 1?h, followed by sustained release afterward. Colloidal stability results of LPNPs in different media showed that particle size and zeta potential values of particles did not change significantly in all media except of FBS 100% for 120?h. Finally, the results of a cellular uptake study showed that LPNPs were significantly taken up by 83.3% in L929 cells.

Conclusion: We concluded that the LPNPs prepared with PCL as polymeric core material and tripalmitin:lechitin mixture as lipid shell should be a promising choice for protein delivery.     

Folate-modified–chitosan-coated liposomes for tumor-targeted drug delivery

In this study, a folate-modified–chitosan-coated liposome (FCCL) was prepared for tumor-targeted drug delivery. The folate–chitosan conjugates were characterized using ¹H NMR and infrared spectrum analysis. The properties of folate–chitosan-coated liposomes (FCCLs) were studied and compared with those of traditional liposomes and chitosan-coated liposomes (CCLs). FCCLs were spherical in shape with a classic core–shell structure. Compared with conventional liposomes, FCCLs had larger size (average diameter: 182.0 nm), higher zeta potential (10.1 mV), prolonged drug release behaviors (55.76 % after 24 h), and better physical stability when stored at 25 °C, all similar to the properties of CCLs. With fluorescein as a model drug, fluorescein-loaded liposomes, CCLs, and FCCLs were prepared and their tumor targeting ability was evaluated according to the in vitro cellular uptake of fluorescein loaded nanoparticles by MCF-7 and HUVEC cells. Results demonstrated that FCCLs had a significant higher uptake by folate receptor positive cells (MCF-7) as compared to traditional liposomes and CCLs, which indicated that the FCCLs were promising nano-carriers for tumor-targeted drug delivery.     

Development and In Vitro Evaluation of Surface Modified Poly(lactide-co-glycolide) Nanoparticles with Chitosan-4-Thiobutylamidine

ABSTRACT

The objective of this study was to develop a nanoparticulate drug delivery system based on the surface modification of poly(lactide-co-glycolide) (PLGA) nanoparticles with a thiolated chitosan. PLGA nanoparticles were prepared by the emulsification-solvent evaporation method. Immobilization of chitosan to the surface of PLGA nanoparticles via amide bonds was mediated by a carbodiimide. Thiol groups were covalently bound to the chitosan surface of particles by reaction with 2-iminothiolane. Obtained nanoparticles were characterized in vitro regarding size, zeta potential, thiol group content, stability at different pH values, mucoadhesion, and drug release. Results demonstrated that the surface modification of PLGA nanoparticles with thiolated chitosan (chitosan-TBA) leads to nanoparticles of a mean diameter of 889.5 ± 72 nm and positive zeta potential of + 24.74 mV. The modified nanoparticles contained 7.32 ± 0.24 μmol thiol groups per gram nanoparticles. The size of nanoparticles was strongly influenced by the pH of the surrounding medium, being 925.0 ± 76.3 nm at pH 2 and 577.8 ± 66.7 nm at pH 7.4. Thiolated nanoparticles showed a 3.3-fold prolonged residence time on the mucosa and an unchanged release profile in comparison to unmodified PLGA nanoparticles. These data suggest that surface modified chitosan-TBA conjugate PLGA nanoparticles have the potential to be used as mucoadhesive drug delivery system.     

Enhanced antithrombotic effect of hirudin by bovine serum albumin nanoparticles

The aim of this study was to design hirudin-loaded bovine serum albumin (BSA) nanoparticles to control release and improve antithrombotic effect of hirudin. BSA nanoparticles were designed as carriers for delivery of hirudin. Hirudin–BSA nanoparticles were prepared by a desolvation procedure and cross linked on the wall material of BSA. The hirudin–BSA nanoparticles were characterised by particle size distribution, zeta potential, entrapment efficiency, differential scanning calorimetry (DSC), and powder X-ray diffractometry (PXRD). The in vitro release characteristics and pharmacological availability were investigated. The morphology of hirudin–BSA nanoparticles was approximately spherical. The mean particle size was 164.1 ± 5.40 nm and the zeta potential was ?20.41 ± 0.64 mV. The mean entrapment efficiency and drug loading were 85.14% ± 4.79% and 66.38% ± 3.54%, respectively. Results from DSC and PXRD revealed that hirudin in BSA existed in an amorphous state. The release behaviours of hirudin from BSA nanoparticles in phosphate buffer solution were fitted to the bioexponential model. The in vivo result obtained after intravenous injection of hirudin–BSA nanoparticles in normal rats demonstrated that BSA nanoparticles could prolong the antithrombotic effect of hirudin in comparison with hirudin solution. These results suggest that hirudin–BSA nanoparticles may be a promising drug delivery system for thrombosis and disseminated intravascular coagulation therapy.     

Polymer-coated CoFe<Subscript>2</Subscript>O<Subscript>4</Subscript> nanoassemblies as biocompatible magnetic nanocarriers for anticancer drug delivery

In this work, we report the preparation of cobalt ferrite nanoparticles (CFNPs) coated with hydrophilic polymers guar gum, gum arabic and poly (methacrylic acid) as magnetic nanocarriers and study their conjugation with doxorubicin for the drug release under applied magnetic field. The effect of polymer coating on structural properties is studied using Fourier transform infrared spectroscopy and powder X-ray diffractometry (XRD). The XRD analysis revealed that the polymer coating on the as-synthesized CFNPs has no influence on their crystallite size and it remains between 18 nm and 19 nm. The characteristic morphology, topography and the evidences of polymer coating over the CFNPs are investigated using scanning electron microscopy, atomic force microscopy and thermogravimetric analysis, respectively. Vibrating sample magnetometry revealed the ferromagnetic nature of uncoated CFNPs with a significant saturation magnetization ～77.2 emu g^?1. The dynamic light scattering measurements are also performed to determine the size of uncoated and coated CFNPs. UV–Visible spectroscopy demonstrated a profound loading (70–75%) of doxorubicin onto the magnetic nanocarriers and the efficient release of drug in the presence of external applied magnetic field. In vitro cytotoxic studies confirmed the cytocompatibility mode of coated CFNPs against Chinese Hamster Ovary and Huh-7 cell line, while 0.2 mg mL^?1 dose of drug-loaded magnetic nanocarriers inhibited the cell viability of Huh-7 up to 60%. These results strongly encourage the utilization of biocompatible magnetic nanocarriers in targeted drug delivery territory.     

Fibrin nanoconstructs: a novel processing method and their use as controlled delivery agents

Fibrin nanoconstructs (FNCs) were prepared through a modified water-in-oil emulsification-diffusion route without the use of any surfactants, resulting in a high yield synthesis of fibrin nanotubes (FNTs) and fibrin nanoparticles (FNPs). The fibrin nanoconstructs formed an aligned structure with self-assembled nanotubes with closed heads that eventually formed spherical nanoparticles of size ~250 nm. The nanotubes were typically ~700 nm long and 150-300 nm in diameter, with a wall thickness of ~50 nm and pore diameter of about 150-250 nm. These constructs showed high stability against aggregation indicated by a zeta potential of -44 mV and an excellent temperature stability upto 200 °C. Furthermore, they were found to be enzymatically degradable, thereby precluding any long term toxicity effects. These unique fibrin nanostructures were analyzed for their ability to deliver tacrolimus, an immunosuppressive drug that is used widely to prevent the initial phase of tissue rejection during allogenic transplantation surgeries. Upon conjugation with tacrolimus, a drug encapsulation efficiency of 66% was achieved, with the in vitro release studies in PBS depicting a sustained and complete drug release over a period of one week at the physiological pH of 7.4. At a more acidic pH, the drug release was very slow, suggesting their potential for oral-intestinal drug administration as well. The in vivo drug absorption rates analyzed in Sprague Dawley rats further confirmed the sustained release pattern of tacrolimus for both oral and parenteral delivery routes. The novel fibrin nanoconstructs developed using a green chemistry approach thus proved to be excellent biodegradable nanocarriers for oral as well as parenteral administrations, with remarkable potential also for delivering specific growth factors in tissue engineering scaffolds.     

Preparation,characterisation and in vitro cytotoxicity studies of chelerythrine-loaded magnetic Fe3O4@O-carboxymethylchitosan nanoparticles

In this work, a novel, active tumour-targeting system (Fe₃O₄@OCMCS-CHE) was designed by surface-modifying superparamagnetic iron oxide nanoparticles (Fe₃O₄) with O-carboxymethylchitosan (OCMCS) to improve their biocompatibility and ability to target specific tumour cells. The chelerythrine (CHE) was used as the model of anti-tumour drug in this system. The optimised formulation was characterised and confirmed by scanning electron microscopy (SEM), transmission electron microscope (TEM), vibrating sample magnetometer (VSM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), in vitro drug release and so on. It was found that the synthesised nanoparticles were spherical in shape with an average size of 60 nm, the drug loading content and entrapment efficiency were 8.32 ± 0.25% (w/w) and 90.65 ± 0.46% (w/w), respectively, and the saturated magnetisation reached 27.06 emu/g. The in vitro drug-release behaviour from nanoparticles displayed a biphasic drug-release pattern with initial burst release and consequently sustained release. Also, the effect of magnetic targeted nanoparticles on the proliferation of human hepatoma cell line (HepG2) in vitro was investigated. The results from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and Hochest assays suggested that the Fe₃O₄@OCMCS-CHE nanoparticles could effectively inhibit the proliferation of HepG2 cells, which displayed time-dependent and concentration-dependent manner. All these results indicated that the multifunctional Fe₃O₄@OCMCS nanoparticles possess a high drug loading efficiency, have low cytotoxicity, and are promising candidates for targeted drug delivery.     

BÜCHI nano spray dryer B-90: a promising technology for the production of metformin hydrochloride-loaded alginate–gelatin nanoparticles

Abstract

The current study aimed to formulate gelatin/sodium alginate nanoparticles utilizing BÜCHI nano spray dryer B-90. Nanoparticles possess many of the advantages including new routes of drug administrations and sustained release properties. Utilizing B-90 technology, metformin hydrochloride (MET) nanoparticles were successfully developed. Preformulation studies such as atomization head mesh size, flow rate, head temperature, polymer viscosity, and surface tension, were adjusted. Additionally, post-formulation characters such as particle size, flowability, surface scan, and dissolution profiles, were evaluated. Spray head (7 µm hole), flow rate (3.5?ml/min) and head temperature (120?°C) were optimized. Polymer viscosity was less than 11.2 cP with a surface tension less than 70.1?dyne/cm. Moreover, anti-diabetic effects of MET formulations were evaluated in streptozotocin-induced diabetic rats. Here, discrete, non-aggregated free-flowing nanoparticle powders with a particle size less than 850?nm were generated. Gelatin/sodium-alginate (1:3) produced nanoparticles were successfully sustained by the in vitro release profile of the drug. In vivo evaluations of the previous formula showed a significant reduction of blood glucose level over 24?h. In conclusion, Nano Spray Dryer B-90 (Büchi Labortechnik AG, Flawil, Switzerland) offers a promising technology for nanoparticles formulation as controlled drug delivery systems enhancing compliance of type-II diabetic patients.     

Topical phenytoin nanostructured lipid carriers: design and development

Phenytoin (PHT) is an antiepileptic drug that was reported to exhibit high wound healing activity. Nevertheless, its limited solubility, bioavailability, and inefficient distribution during topical administration limit its use. Therefore, this study aims to develop, characterize nanostructured lipid carriers (NLCs), and evaluate their potential in topical delivery of PHT to improve the drug entrapment efficiency and sustained release. The NLCs were prepared by hot homogenization followed by ultra sonication method using 2³ factorial design. NLC formulations were characterized regarding their particle size (PS), zeta potential (ZP), entrapment efficiency percent (%EE), surface morphology, physicochemical stability, and in vitro release studies. The optimized NLC (F7) was further incorporated in 1%w/v carbopol gel and then characterized for appearance, pH, viscosity, stability, and in vitro drug release. The prepared NLCs were spherical in shape and possessed an average PS of 121.4–258.2?nm, ZP of (?15.4)–(–32.2)?mV, and 55.24–88.80 %EE. Solid-state characterization revealed that the drug is dispersed in an amorphous state with hydrogen bond interaction between the drug and the NLC components. NLC formulations were found to be stable at 25?°C for six months. The stored F7-hydrogel showed insignificant changes in viscosity and drug content (p>.05) up to six?months at 25?°C that pave a way for industrial fabrication of efficient PHT products. In vitro release studies showed a sustained release from NLC up to 48?h at pH 7.4 following non-Fickian Higuchi kinetics model. These promising findings encourage the potential use of phenytoin loaded lipid nanoparticles for future topical application.     

Development and characterization of coated-microparticles based on whey protein/alginate using the Encapsulator device

The aim of this study is to prepare whey protein (WP)-based microparticles (MP) using the Encapsulator^® device. The viscosity dependence of the extrusion device required to mix WP with a food-grade and less viscous polymer. Mixed WP/ALG MP were obtained with the optimized WP/alginate (ALG) ratio (62/38). These particles were further coated with WP or ALG using non-traumatic and solvent-free coating process developed in this study. Size and morphology of coated and uncoated MP were determined. Then, swelling and degradation (WP release) of formulations were investigated in pH 1.2 and 7.5 buffers and in simulated gastric and intestinal fluids (SGF, SIF) and compared to pure ALG and pure WP particle behaviours. At pH 1.2, pure ALG shrank and pure WP swelled, whereas the sizes of mixed WP/ALG matrix were stable. In SGF, WP/ALG MP resisted to pepsin degradation compare to pure WP particles due to ALG shrinkage which limited pepsin diffusion within particles. Coating addition with WP or ALG slowed down pepsin degradation. At pH 7.5, WP/ALG particles were rapidly degraded due to ALG sensitivity but the addition of a WP coating limited effectively the swelling and the degradation of MP. In SIF, pancreatin accelerated MP degradation but ALG-coated MP exhibited interesting robustness. These results confirmed the interest and the feasibility to produce coated WP-based MP which could be a potential orally controlled release drug delivery system.     

Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine

The objective of this study was to develop a nanoparticulate drug delivery system based on the surface modification of poly(lactide-co-glycolide) (PLGA) nanoparticles with a thiolated chitosan. PLGA nanoparticles were prepared by the emulsification-solvent evaporation method. Immobilization of chitosan to the surface of PLGA nanoparticles via amide bonds was mediated by a carbodiimide. Thiol groups were covalently bound to the chitosan surface of particles by reaction with 2-iminothiolane. Obtained nanoparticles were characterized in vitro regarding size, zeta potential, thiol group content, stability at different pH values, mucoadhesion, and drug release. Results demonstrated that the surface modification of PLGA nanoparticles with thiolated chitosan (chitosan-TBA) leads to nanoparticles of a mean diameter of 889.5 ± 72 nm and positive zeta potential of + 24.74 mV. The modified nanoparticles contained 7.32 ± 0.24 μmol thiol groups per gram nanoparticles. The size of nanoparticles was strongly influenced by the pH of the surrounding medium, being 925.0 ± 76.3 nm at pH 2 and 577.8 ± 66.7 nm at pH 7.4. Thiolated nanoparticles showed a 3.3-fold prolonged residence time on the mucosa and an unchanged release profile in comparison to unmodified PLGA nanoparticles. These data suggest that surface modified chitosan-TBA conjugate PLGA nanoparticles have the potential to be used as mucoadhesive drug delivery system.     

Development of pH-sensitive pectinate/alginate microspheres for colon drug delivery

The purposes of this study were to develop and evaluate calcium pectinate/alginate microspheres (PAMs) and to exploit their pH-sensitive properties for colon-targeted delivery of encapsulated cisplatin. PAMs were prepared using an electrospraying method. The PAMs, as cores, were then coated with Eudragit S100 using a polyelectrolyte multilayer coating technique in aqueous solution. The morphology of the microspheres was observed under scanning electron microscopy. In vitro drug release studies were performed in simulated gastrointestinal fluid, and the results indicated that approximately 5 % of the cisplatin was released from the Eudragit S100-coated PAMs, and 51 % of the cisplatin was released from the uncoated PAMs at 1 h. The release of cisplatin from the Eudragit S100-coated PAMs was more sustained in simulated gastric fluid than in simulated intestinal fluid due to the increased solubility of the coating polymer in media with pH >7.0. Drug release from the Eudragit S100-coated PAMs was best described by the Higuchi’s square root model. From these results, it was concluded that Eudragit S100-coated PAMs are a potential carrier for delivery of cisplatin to the colon.     

Sustained delivery of olanzapine from sunflower oil‐based polyol‐urethane nanoparticles synthesised through a cyclic carbonate ring‐opening reaction

The forefront horizon of biomedical investigations in recent decades is parcelling‐up and delivery of drugs to achieve controlled/targeted release. In this regard, developing green‐based delivery systems for a spatiotemporal controlling therapeutic agent have drawn a lot of attention. A facile route based on cyclic carbonate ring‐opening reaction has been utilised to synthesise a bio‐based polyol‐containing urethane bond [polyol‐urethane (POU)] as a nanoparticulate drug delivery system of olanzapine in order to enhance its bioavailability. After characterisation, the nanoparticles were also estimated for in vitro release, toxicity, and pharmacokinetic studies. As olanzapine has shown poor bioavailability and permeability in the brain, the sustained release of olanzapine from the designed carriers could enhance pharmacokinetic effectiveness. POU in the aqueous solution formed micelles with a hydrophobic core and embedded olanzapine under the influence of its hydrophobic nature. Drug release from the nanoparticles (90 ± 0.43 nm in diameter) indicated a specific pattern with initial burst release, and then a sustained release behaviour (82 ± 3% after 168 h), by the Higuchi‐based release mechanism. Pharmacokinetics assessments of POU‐olanzapine nanoparticles were carried in male Wistar rats through intravenous administration. The obtained results paved a way to introduce the POU as an efficient platform to enhance the bioavailability of olanzapine in therapeutic methods.Inspec keywords: hydrophobicity, nanomedicine, nanofabrication, nanoparticles, drug delivery systems, biomedical materials, polymers, brainOther keywords: cyclic carbonate ring‐opening reaction, nanoparticulate drug delivery system, bioavailability, drug release, initial burst release, Higuchi‐based release mechanism, POU‐olanzapine nanoparticles, sunflower oil‐based polyol‐urethane nanoparticles, forefront horizon, biomedical investigations, green‐based delivery systems, spatiotemporal controlling therapeutic agent, bio‐based polyol‐containing urethane bond, polyol‐urethane, toxicity, pharmacokinetic studies, olanzapine, aqueous solution, micelles, hydrophobic core, Pharmacokinetics, male Wistar rats, brain     

Synthesis and in vitro release study of ibuprofen-loaded gelatin graft copolymer nanoparticles

Objective: This work deals with the preparation, characterization and in vitro release study of IBU-loaded gel graft copolymer nanoparticles.

Method: Gelatin (Gel) graft copolymer nanoparticles were prepared using styrene (Sty) and/or 2-hydroxyethyl methacrylate (HEMA) monomers in the presence of potassium persulfate and glutaraldehyde as an initiator and cross-linker, respectively. The prepared nanoparticles as sustained release drug carriers were investigated using the nonsteriodal anti-inflammatory model drug, ibuprofen (IBU).

Results: The prepared nanoparticles as sustained release drug carriers were investigated using the nonsteriodal anti-inflammatory model drug, IBU. The prepared Gel/HEMA and Gel/Sty nanoparticles exhibited particles size ranging from 15 to 17?nm and from 0.42 to 5?mm, respectively. The dissolution of IBU in phosphate buffer, pH 7.4, at 37°C from the prepared nanoparticles was evaluated using UV spectroscopy. In addition, the prepared nanoparticles were characterized using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), transmitting electron microscope (TEM) and zeta potential/particle size analyzer. In vitro dissolution study showed that the dissolution rates of the crosslinked nanoparticles were retarded relative to the uncrosslinked ones. Moreover, the released amount constantly decreases with increasing gluteraldehyde content in the gel nanoparticles.

Conclusion: Crosslinked gel-based graft copolymers exhibited slow IBU release within six hours. Furthermore, results from different characterization techniques such as TEM, particles size and zeta potential measurements confirmed the formation of pH-responsive gel-graft copolymer nanoparticles.